Skip to content
ClinCalc Pro
Menu
Combined HRT patch (oestrogen + progestogen)

Estradiol with levonorgestrel

Brand names: FemSeven Conti, FemSeven Sequi

A combined hormone replacement therapy of estradiol with the progestogen levonorgestrel, used to treat menopausal symptoms in women with a uterus, often as a continuous combined preparation.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Estradiol relieves oestrogen-deficiency symptoms while levonorgestrel opposes endometrial proliferation, allowing a bleed-free regimen in suitably postmenopausal women.

Prescribing in practice

  • Levonorgestrel is present to protect the endometrium against unopposed oestrogen, so it is essential for women who retain a uterus and the product should not be substituted with oestrogen alone.
  • Continuous combined regimens suit women who are clearly postmenopausal; breakthrough bleeding in the early months is common but persistent bleeding needs investigation.
  • Weigh thrombotic, stroke and breast cancer risk and avoid in active thromboembolic disease or oestrogen-dependent malignancy.

Monitoring

Monitor symptom response, blood pressure and bleeding pattern, and investigate bleeding that persists or starts after an initial settled phase.

Counselling the patient

  • Some irregular bleeding or spotting is common in the first few months but report bleeding that persists or recurs.
  • Seek urgent advice for breast changes or symptoms of a clot.
  • Attend routine breast and cervical screening.

Evidence & guidelines

NICE menopause guidance underpins the use of combined continuous oestrogen-progestogen hormone replacement therapy in postmenopausal women.

Reference: NICE NG23; British Menopause Society; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.